Annual costs of rheumatoid arthritis in Turkey

Malhan, S; Akbulut, Lale; Bodur, Hatice; Tulunay, Cankat

doi:10.1007/s00296-009-1040-2

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many observational studies have attempted to estimate the burden of RA, a key limitation is the lack of disease severity measures in datasets [17-20]. …”

Section: Introductionmentioning

confidence: 99%

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Başer

Baser²,

Altınbaş

et al. 2013

Health Econ Rev

View full text Add to dashboard Cite

ObjectiveThis study aimed to apply the previously validated severity index for rheumatoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey and determine the effect of RA severity on health care costs and biologic use.MethodsThis retrospective study used the Turkish national health insurance database MEDULA (June 1, 2009-December 31, 2011). Prevalent RA patients were required to be age 18 to 99, have two RA diagnoses at least 60 days apart and be continuously enrolled 1 year prior to (baseline period) and post (follow-up period) index date, which was the first RA claim during the identification period (June 1, 2010-December 31, 2010). SIFRA was calculated for the baseline period. Total health care costs and biologic use were examined for the follow-up period. The chi-square test was used to determine the association between SIFRA score terciles and outcomes. Generalized linear models were applied to determine health care costs while multivariate logistic regression determined the effect of SIFRA on outcome measures for biologic use.ResultsA total of 1,920 patients were identified. The mean SIFRA score was 14.21, and 7.05 (49.57%) of the mean composed of clinical and functional status variables, followed by 6.32 (44.47%) for medications, 0.48 (3.40%) for radiology and laboratory findings, and 0.32 (2.25%) for extra-articular manifestation. There was a significant variation in scores across cities. After controlling for age, gender, region, and comorbidity index, patients in the high SIFRA tercile were 5.16 times more likely to be prescribed biologics (p<0.001, confidence interval [CI]: 3.46-7.69), and incurred annual health care costs that were €2,091 higher (p<0.001, CI: €1,557 - €2,625) than those in the low SIFRA score tercile.ConclusionRA severity varies throughout Turkey and is a significant determinant of health care costs and biologic therapy use. Therefore, future comparative effectiveness studies should include the severity measure in their analysis.

show abstract

“…Although many observational studies have attempted to estimate the burden of RA, a key limitation is the lack of disease severity measures in datasets [17-20]. …”

Section: Introductionmentioning

confidence: 99%

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Başer

Baser²,

Altınbaş

et al. 2013

Health Econ Rev

View full text Add to dashboard Cite

show abstract

Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database

et al. 2013

View full text Add to dashboard Cite

This study aimed to estimate and identify determinants of direct medical costs associated with rheumatoid arthritis (RA) in Turkey using nationwide real-world data. Using the Turkish National Health Insurance Database (2009-2011), RA patients (ages 18-99) were identified using International Classification of Disease Tenth Revision Clinical Modification (ICD-10-CM) codes. Patients were required to have two RA diagnoses at least 60 days apart and were grouped as prevalent and incident cases. The date of the first RA claim was identified for each patient and designated as the index date. Total healthcare costs were examined over the 12-month period following the index date. Descriptive and multivariate analyses are provided. Generalized linear models were used to calculate expected annual costs for incident and prevalent RA patients after controlling for age, gender, region, comorbid conditions and medication. A total of 2,613 patients met all inclusion criteria (693 incident; 1,920 prevalent patients). Prevalent patients were older, less likely to reside in the Marmara region, had higher comorbidity index scores and were more likely to use non-steroidal anti-inflammatory drugs, biologics and disease-modifying anti-rheumatic drugs relative to incident patients. Average direct annual costs were 2,000 [(1,750, 2,247) 95 % CI] for incident cases and 2,385 [(2,224, 2,545) 95 % CI] for prevalent cases, most due to pharmacy costs (73 % for incident cases, 60 % for prevalent cases). For incident and prevalent cases, a significant portion of inpatient and outpatient costs were due to physician costs (31 % for incident cases, 40 % for prevalent cases). Although the costs were not significantly different in terms of age or region, prior comorbid conditions and medication use significantly affected the cost estimation. RA total annual costs were found to be lower in Turkey, relative to estimates in Europe. The significant portion of the annual costs was due to pharmaceutical expenditures. Comparative effectiveness analysis may be useful to decrease RA-related pharmacy costs.

show abstract

Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

et al. 2020

View full text Add to dashboard Cite

Annual costs of rheumatoid arthritis in Turkey

Cited by 4 publications

References 12 publications

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database

Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

Contact Info

Product

Resources

About